New results with Cefaly in migraine pain published in The Journal of Headache and Pain- Cefaly Technologies

A new study finds that Cefaly, the first FDA-approved transcutaneous electrical nerve stimulation device specifically authorized for use prior to the onset of migraine pain, from Cefaly Technologies, provides relief for 81% of migraine sufferers who use it. The results of the clinical trial, published in The Journal of Headache and Pain, found 24 migraine sufferers who frequently suffered episodic migraines without aura, experienced a very high efficacy when using the headband-like device, for 20-minutes per day, at least two-thirds of the required 60-day consecutive treatment period.

The entire study was conducted from January 2013 to October 2014. The test group matched the category of patients in a 2,313 person study used to gain the approval of the Food and Drug Administration in March 2014. Those results were also published in The Journal of Headache and Pain, in December 2013. The new study is the first to reveal the intensity of headache pain during a migraine attack is significantly reduced using the Cefaly device. Previous studies only focused on migraine prevention.